Navigation Links
Video: BSP Pharma Inc. Announces Groundbreaking Findings from The Australian Centre for Complementary Medicine Education and Research Joint Health Clinical Study
Date:11/14/2007

Research has indicated that FlexNow(R) Joint Formula shows significant reductions in cartilage deterioration, joint inflammation, and joint pain.

EGG HARBOR TWP., N.J., Nov. 14 /PRNewswire/ -- BSP Pharma Inc., the maker and distributor of FlexNow(R) Joint Formula, has announced the findings from the new joint health clinical study completed this past June at the Australian Centre for Complementary Medicine Education and Research (ACCMER) in Brisbane, Australia led by Dr. Phillip Cheras PhD.

(Photo: http://www.newscom.com/cgi-bin/prnh/20071114/NEW031 )

To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/flexnow/29883/

Results show that, for those with elevated cartilage deterioration in their joints, FlexNow Joint Formula provides an unprecedented reduction in cartilage deterioration for a natural product, 44% higher than that reported for glucosamine.(1) This is the first human clinical study of a natural product showing such a great reduction in a well recognised marker for cartilage deterioration as well as significant reductions in joint specific inflammation and joint pain.

FlexNow is an all natural dietary supplement made with one ingredient, an extract from the shea nut which contains one of the most powerful inflammation fighters of any known plant. The ability of shea extract to reduce inflammation in the human body has only recently been discovered.

Dr. Cheras' was asked to be the principal investigator due to his ground breaking research showing it is highly likely that most joint problems are a vascular condition. Prior to this study, research had indicated that FlexNow had a strong ability to address this cause, and not just the symptoms of joint health.

"FlexNow shows great promise and BSP's approach to bringing this product to market is a model for responsible development for complementary medicine," said Cheras.

The research was designed to bring together a large number of previous studies, to confirm the efficacy of shea extract in humans and to further demonstrate the safety of FlexNow. FlexNow is one of only 7 dietary supplements to be accepted by the FDA in 2004 as meeting all safety requirements, which was further shown during the clinical study when there was no difference in adverse effects between FlexNow and placebo.

The biggest clinical surprise was the unprecedented reduction in the breakdown of cartilage, both compared to placebo and for that reported for glucosamine. The other remarkable findings were the strong reduction in inflammatory markers that are produced more in unhealthy joints and joint cartilage than normal joints, and high sensitivity C-reactive protein (hsCRP), which has been found to be higher in patients with unhealthy joints than controls.

"This clinical confirmation that FlexNow is significantly reducing cartilage breakdown and inflammation, gives us insight into why so many FlexNow Joint Formula users are telling us of their joint relief for the first time," said Leonard P. Smith, CEO and President, BSP Pharma Inc., "which is allowing so many people with joint pain to once again lead an active life."

The clinical study is being submitted for publication. Prior clinical studies can be found by visiting http://www.flexnow.us

(1) Christgau S, Henrotin Y, Tanko LB, et al. Osteoarthritic patients with

high cartilage turnover show increased responsiveness to the cartilage

protecting effects of glucosamine sulphate. Clin Exp Rheumatol 2004;

22:36-42.


'/>"/>
SOURCE BSP Pharma Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Video: Nutrition Comes to NASCAR
2. Video: Circulatory Care of New Jersey
3. Video: GEN Video Hits Home with Web Audience
4. Video: Beyond the Red Door: Gildas Club Worldwide and DKNY Host Successful Benefit Event
5. Video: Food Expert B. Smith to Provide Healthy Menu Makeovers
6. Video: New FDA-Approved Sun Protectant Saves Skin All Year Round
7. Video: Kyphon Supports World Osteoporosis Day on October 20, 2007 to Raise Awareness of Osteoporosis and Spinal Fracture Risk
8. Video: Trinity Mother Frances Neurosurgeon First in Region to Remove Brain Tumor Using Unique Surgical Procedure
9. Video: Holiday Safety Is Important
10. Video: Grin Big With an Award-Winning Smile
11. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... FL (PRWEB) , ... April 26, 2017 , ... ... and human performance, is proud to announce that it has received 510(k) clearance ... technologies, the MyoCycle Home and the MyoCycle Pro. , Both devices are stationary ...
(Date:4/25/2017)... ... April 25, 2017 , ... Splashtop Inc. , the ... This new addition to the Mirroring360 product family combines device screen mirroring with ... Pro enables educators, business professionals and individuals to stream or mirror app screens, ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... awareness for Duchenne muscular dystrophy, and funding for Duchenne research, congratulates Capricor ... I/II HOPE clinical trial in Duchenne announced today. , Coalition Duchenne funded ...
(Date:4/25/2017)... ... April 25, 2017 , ... As President Trump challenges ... for how his administration could impact the employee benefits industry. James Slotnick, AVP, ... most likely to make it through Congress. His discussion will focus on the ...
(Date:4/25/2017)... ... April 25, 2017 , ... The doctors at Wall Centre Dental are ... dental fear and require sedation to receive dental care. The doctors offer three treatment ... from hygienic cleanings to oral surgery, at their dental office in Vancouver. Wall Centre ...
Breaking Medicine News(10 mins):
(Date:4/18/2017)... 18, 2017  Cardinal Health (NYSE: CAH ... 2017 earnings per share (EPS) guidance and providing a ... in conjunction with this morning,s announcement of the planned ... Nutritional Insufficiency businesses. Cardinal Health now believes ... be at the bottom of its previous guidance range ...
(Date:4/18/2017)... -- Research and Markets has announced the addition of ... offering. ... market to grow at a CAGR of 6.35% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
(Date:4/18/2017)... SUNNYVALE, Calif. , April 18, 2017 /PRNewswire/ ... results of collaboration started in 2016, in which ... "Artificial Brain SOINN". The companies achieved initial results ... ultrasound solution by Artificial Brain SOINN. The results ... Tokyo Big Sight, April 19-21, at booths 4505 ...
Breaking Medicine Technology: